ISE High Income PR (YLDA) News

Form 8-K - Current report

Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty

– Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905...

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in...

Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in...

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in...

Agios Reports Business Highlights and First Quarter 2024 Financial Results

– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent...

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in...

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

– Report Highlights Company’s Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in...